Your browser doesn't support javascript.
loading
Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy.
Geisen, Will R; Berger, Justin; Schwartz, Chelsea; Reddy, Abhimanyu; Rai, Balaj; Wadih, George; Peck, Joshua.
Affiliation
  • Geisen WR; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Berger J; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Schwartz C; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Reddy A; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Rai B; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Wadih G; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
  • Peck J; Ohio Gastroenterology and Liver Institute, Cincinnati, OH, United States.
IDCases ; 22: e00962, 2020.
Article in En | MEDLINE | ID: mdl-32983888
ABSTRACT
The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IDCases Year: 2020 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IDCases Year: 2020 Document type: Article Affiliation country: United States